- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Clinic visit, Baseline visit
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Sacramento, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–78
of 78
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Elafibranor 80 mg, Elafibranor 120 mg, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
- Interventions
- TruGraf®
- Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- St Louis, Missouri
- Conditions
- Primary Biliary Cholangitis
- Interventions
- EDP-305 1 mg, EDP-305 2.5 mg, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 40
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more
- Conditions
- Hepatobiliary Diseases
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Liver Cirrhosis, Biliary
- Interventions
- INT-747, Ursodeoxycholic Acid (URSO), Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more